This MAPP establishes procedures for identifying review issues during the filing review of all original new drug applications (NDAs), original biologics license applications (BLAs), and efficacy supplements within the Center for Drug Evaluation and Research (CDER) and outlines the procedures for informing the applicant about these issues. It does not apply to labeling supplements that contain clinical data.